Enitociclib

From Wikipedia, the free encyclopedia
Enitociclib
Identifiers
  • 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H18F2N4O2S
Molar mass404.44 g·mol−1
3D model (JSmol)
  • COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)C[S@@](=N)(=O)C
  • InChI=nChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1
  • Key:YZCUMZWULWOUMD-NDEPHWFRSA-N

Enitociclib is an experimental drug that is being investigated for the treatment of cancer.[1] It is an inhibitor of the kinase CDK9.[2][3]

References[edit]

  1. ^ "Enitociclib - Vincerx Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Morillo D, Vega G, Moreno V (August 2023). "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies". Oncotarget. 14: 749–752. doi:10.18632/oncotarget.28473. PMC 10408673. PMID 37552223.
  3. ^ Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, et al. (November 2023). "Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription". Cancer Research Communications. 3 (11): 2268–2279. doi:10.1158/2767-9764.CRC-23-0219. PMC 10634346. PMID 37882668.